Intrinsic resistance of solid tumors to immune checkpoint blockade therapy

Xianda Zhao, Subbaya Subramanian

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity. The properties of the tumor microenvironment control T-cell infiltration, distribution, and function in tumor tissues. Low tumor immunogenicity and a strong immunosuppressive tumor microenvironment cause significant intrinsic resistance to ICBT. With our evolving understanding of intrinsic resistance, people have successfully tested, in preclinical models, treatments targeting specific resistance mechanisms to sensitize ICBT-resistant tumors. Translation of those preclinical findings to the clinical arena will help generate personalized ICBT strategies that target tumorspecific resistance mechanisms. Progress in the new personalized ICBT strategies will expand the reach of immunotherapy to more cancer types, thus enabling more patients to benefit.

Original languageEnglish (US)
Pages (from-to)817-822
Number of pages6
JournalCancer Research
Volume77
Issue number4
DOIs
StatePublished - Feb 15 2017

Fingerprint

Neoplasms
Tumor Microenvironment
Therapeutics
Immunosuppressive Agents
Immunotherapy
Immunity
T-Lymphocytes
Mutation

Cite this

Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. / Zhao, Xianda; Subramanian, Subbaya.

In: Cancer Research, Vol. 77, No. 4, 15.02.2017, p. 817-822.

Research output: Contribution to journalReview article

@article{6854d536daa1448cb9ee2610a7146ee4,
title = "Intrinsic resistance of solid tumors to immune checkpoint blockade therapy",
abstract = "Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity. The properties of the tumor microenvironment control T-cell infiltration, distribution, and function in tumor tissues. Low tumor immunogenicity and a strong immunosuppressive tumor microenvironment cause significant intrinsic resistance to ICBT. With our evolving understanding of intrinsic resistance, people have successfully tested, in preclinical models, treatments targeting specific resistance mechanisms to sensitize ICBT-resistant tumors. Translation of those preclinical findings to the clinical arena will help generate personalized ICBT strategies that target tumorspecific resistance mechanisms. Progress in the new personalized ICBT strategies will expand the reach of immunotherapy to more cancer types, thus enabling more patients to benefit.",
author = "Xianda Zhao and Subbaya Subramanian",
year = "2017",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-16-2379",
language = "English (US)",
volume = "77",
pages = "817--822",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Intrinsic resistance of solid tumors to immune checkpoint blockade therapy

AU - Zhao, Xianda

AU - Subramanian, Subbaya

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity. The properties of the tumor microenvironment control T-cell infiltration, distribution, and function in tumor tissues. Low tumor immunogenicity and a strong immunosuppressive tumor microenvironment cause significant intrinsic resistance to ICBT. With our evolving understanding of intrinsic resistance, people have successfully tested, in preclinical models, treatments targeting specific resistance mechanisms to sensitize ICBT-resistant tumors. Translation of those preclinical findings to the clinical arena will help generate personalized ICBT strategies that target tumorspecific resistance mechanisms. Progress in the new personalized ICBT strategies will expand the reach of immunotherapy to more cancer types, thus enabling more patients to benefit.

AB - Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity. The properties of the tumor microenvironment control T-cell infiltration, distribution, and function in tumor tissues. Low tumor immunogenicity and a strong immunosuppressive tumor microenvironment cause significant intrinsic resistance to ICBT. With our evolving understanding of intrinsic resistance, people have successfully tested, in preclinical models, treatments targeting specific resistance mechanisms to sensitize ICBT-resistant tumors. Translation of those preclinical findings to the clinical arena will help generate personalized ICBT strategies that target tumorspecific resistance mechanisms. Progress in the new personalized ICBT strategies will expand the reach of immunotherapy to more cancer types, thus enabling more patients to benefit.

UR - http://www.scopus.com/inward/record.url?scp=85014047680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014047680&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-2379

DO - 10.1158/0008-5472.CAN-16-2379

M3 - Review article

C2 - 28159861

AN - SCOPUS:85014047680

VL - 77

SP - 817

EP - 822

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -